今日焦点！美团强势回购股份 彰显发展信心

美团强势回购股份 彰显发展信心

北京 - 2024年6月14日，美团-W（03690）在香港交易所公告，公司于当日斥资5亿港元回购432.78万股公司B类股份，回购价格介于每股114港元至117.9港元之间。此次回购是美团继去年12月启动10亿美元回购计划后，再次出手回购股份。

美团表示，公司回购股份是基于对自身业务发展前景的信心，以及对公司长期价值的坚定信念。回购股份将有助于减少公司股份数量，提升每股收益，并向股东回馈利润。

美团回购背后的深层逻辑

分析人士认为，美团此次回购股份背后主要有以下几个原因：

• **公司盈利能力持续增强。**美团2024年第一季度财报显示，公司实现营收429.5亿元，同比增长25.2%；经调整净利润69.7亿元，同比增长24.4%。公司盈利能力持续增强，为回购股份提供了充足的资金支持。
• **公司发展前景看好。**美团作为中国领先的即时配送和餐饮外卖平台，拥有庞大的用户基数和丰富的业务场景。随着中国经济的持续增长和居民消费水平的不断提高，美团的未来发展前景十分广阔。
• **回购股份有利于提振股价。**美团股价近期有所下跌，回购股份可以减少公司股份数量，提升每股收益，并向市场传递公司管理层对公司未来发展的信心，从而提振股价。

美团回购股份对投资者有何影响

美团回购股份对投资者主要有以下几方面影响：

• **提升每股收益。**回购股份后，公司每股流通股数量减少，摊薄后的每股收益将有所提升，有利于提高股东的投资回报。
• **增强股价稳定性。**公司回购股份可以减少市场上的流通股数量，从而增强股价的稳定性，降低股价波动性。
• **传递积极信号。**公司回购股份表明公司管理层对公司未来发展充满信心，这将提升投资者对公司的信心，吸引更多投资者买入股票。

总体而言，美团此次回购股份是公司积极回馈股东、增强发展信心的重要举措，有利于提升公司长期价值，并为投资者带来长期的投资回报。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.